Faeth Therapeutics, Inc.
FTH- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001829802
In the last 90 days, Faeth Therapeutics, Inc. insiders filed 1 open-market purchase and 0 sales; 45 institutions reported holding it in 13F filings for Q2 2026, worth $333.8M in total; no superinvestor holds it.
13F holders, Q4 2024
Institutional positions in Faeth Therapeutics, Inc. as of Dec 31, 2024. Investment managers with $100 million or more in US stocks report their long positions on Form 13F within 45 days after each quarter ends. How 13F works
- Institutional holders
- 24
- +6 vs. Q3 2024
- Shares held
- 2.36M
- +177.3K (+8.1%) vs. Q3 2024
- Total value
- $1.16M
- −$149.8K (−11.5%) vs. Q3 2024
- New holders
- 7
- 1 more added
- Sold out
- 1
- 11 more reduced
1 institution that held it in Q3 2024 haven't filed for Q4 2024 yet. Not filing isn't selling, so they aren't counted as sold out or in the changes above.
Compare with Q3 2024: new holders, sold out and not filed yet
Holders and value by quarter
Institutions reporting FTH on Form 13F each quarter since Q1 2021, and the total value they reported. Values are as of each quarter end, so they also move with the share price.
| Quarter | Holders | Value |
|---|---|---|
| Q2 2026 | 45 | $333.8M |
| Q1 2026 | 30 | $68.0M |
| Q4 2025 | 10 | $514.8K |
| Q3 2025 | 9 | $466.2K |
| Q2 2025 | 10 | $600.0K |
| Q1 2025 | 20 | $760.2K |
| Q4 2024 | 24 | $1.16M |
| Q3 2024 | 19 | $1.32M |
| Q2 2024 | 24 | $1.31M |
| Q1 2024 | 25 | $2.43M |
| Q4 2023 | 24 | $2.05M |
| Q3 2023 | 23 | $2.38M |
| Q2 2023 | 26 | $3.58M |
| Q1 2023 | 27 | $4.71M |
| Q4 2022 | 28 | $3.93M |
| Q3 2022 | 31 | $4.47M |
| Q2 2022 | 40 | $7.06M |
| Q1 2022 | 43 | $8.21M |
| Q4 2021 | 38 | $19.7M |
| Q3 2021 | 42 | $37.1M |
| Q2 2021 | 34 | $22.7M |
| Q1 2021 | 40 | $45.8M |
Institutions, Q4 2024
Shares, value and share of portfolio for each institution holding Faeth Therapeutics, Inc.; share changes are against Q3 2024.
| Institution | Shares | Value | % of portfolio | Change in shares | Action |
|---|---|---|---|---|---|
| Ikarian Capital, LLC | 649,963 | $318.5K | 0.09% | −370.0% | Reduced |
| Vanguard Group Inc | 594,454 | $291.3K | 0.00% | −24,303−3.9% | Reduced |
| Catalio Capital Management, LP | 294,374 | $144.3K | 0.03% | +294,374 | New |
| Boothbay Fund Management, LLC | 172,798 | $84.7K | 0.00% | −370.0% | Reduced |
| Renaissance Technologies LLC | 156,800 | $76.8K | 0.00% | −58,772−27.3% | Reduced |
| Geode Capital Management, LLC | 148,887 | $73.0K | 0.00% | −14,252−8.7% | Reduced |
| XTX Topco Ltd | 62,903 | $30.8K | 0.00% | +48,977+351.7% | Added |
| Citadel Advisors LLC | 57,717 | $28.3K | 0.00% | −8,327−12.6% | Reduced |
| Bridgeway Capital Management, LLC | 47,900 | $23.5K | 0.00% | 00.0% | Unchanged |
| Susquehanna International Group, LLP | 38,051 | $18.6K | 0.00% | −52,377−57.9% | Reduced |
| Northern Trust Corp | 25,983 | $12.7K | 0.00% | 00.0% | Unchanged |
| State Street Corp | 25,774 | $12.6K | 0.00% | 00.0% | Unchanged |
| Cresset Asset Management, LLC | 19,671 | $9.64K | 0.00% | 00.0% | Unchanged |
| NWF Advisory Services Inc. | 16,514 | $8.09K | 0.00% | +16,514 | New |
| Raymond James Financial Inc | 14,000 | $6.86K | 0.00% | +14,000 | New |
| Deuterium Capital Management, LLC | 11,000 | $5.39K | 0.01% | 00.0% | Unchanged |
| HRT Financial LP | 11,600 | $5.00K | 0.00% | +11,600 | New |
| Morgan Stanley | 9,219 | $4.52K | 0.00% | −3,000−24.6% | Reduced |
| Tower Research Capital LLC (TRC) | 5,448 | $2.67K | 0.00% | −1,581−22.5% | Reduced |
| JPMorgan Chase & Co | 705 | $345 | 0.00% | −2−0.3% | Reduced |
| BNP Paribas Arbitrage, SA | 160 | $78 | 0.00% | +160 | New |
| Bank of America Corp | 136 | $67 | 0.00% | −122−47.3% | Reduced |
| SBI Securities Co., Ltd. | 71 | $35 | 0.00% | +71 | New |
| UBS Group AG | 2 | $1 | 0.00% | +2 | New |
| National Bank of Canada | 0 | $0 | 0.00% | −45,575−100.0% | Sold out |
| Raymond James & Associates | – | – | – | – | Not filed |